PL4218753T3 - Nowe inhibitory lipazy i ich zastosowania - Google Patents

Nowe inhibitory lipazy i ich zastosowania

Info

Publication number
PL4218753T3
PL4218753T3 PL22197886.9T PL22197886T PL4218753T3 PL 4218753 T3 PL4218753 T3 PL 4218753T3 PL 22197886 T PL22197886 T PL 22197886T PL 4218753 T3 PL4218753 T3 PL 4218753T3
Authority
PL
Poland
Prior art keywords
lipase inhibitor
novel lipase
novel
inhibitor
lipase
Prior art date
Application number
PL22197886.9T
Other languages
English (en)
Polish (pl)
Inventor
Sampath-Kumar Anandan
Kevin GREENMAN
Zeeshan KAMAL
Vijay P. Singh
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of PL4218753T3 publication Critical patent/PL4218753T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12Beta-lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
PL22197886.9T 2017-07-12 2018-07-12 Nowe inhibitory lipazy i ich zastosowania PL4218753T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531454P 2017-07-12 2017-07-12

Publications (1)

Publication Number Publication Date
PL4218753T3 true PL4218753T3 (pl) 2026-04-20

Family

ID=65002124

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22197886.9T PL4218753T3 (pl) 2017-07-12 2018-07-12 Nowe inhibitory lipazy i ich zastosowania
PL18831486.8T PL3651784T3 (pl) 2017-07-12 2018-07-12 Związki do zmniejszania uszkodzeń lipotoksycznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18831486.8T PL3651784T3 (pl) 2017-07-12 2018-07-12 Związki do zmniejszania uszkodzeń lipotoksycznych

Country Status (14)

Country Link
US (5) US11339126B2 (https=)
EP (2) EP3651784B1 (https=)
JP (1) JP7224331B2 (https=)
KR (1) KR102679975B1 (https=)
CN (1) CN111343999B (https=)
AU (2) AU2018300985B2 (https=)
BR (1) BR112020000635B1 (https=)
CA (1) CA3069526A1 (https=)
DK (1) DK4218753T3 (https=)
ES (1) ES2934883T3 (https=)
IL (1) IL271884B2 (https=)
PL (2) PL4218753T3 (https=)
SG (1) SG11202000239XA (https=)
WO (1) WO2019014434A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000239XA (en) 2017-07-12 2020-02-27 Mayo Found Medical Education & Res Compounds for the reducing lipotoxic damage
MX2023012532A (es) * 2021-04-23 2023-11-29 Panafina Inc Metodos de sintetizacion de derivados de lipstatina.
CN114560887B (zh) * 2022-02-15 2024-01-26 安徽美致诚药业有限公司 一种制备奥利司他的中间体的制备方法
AU2023243617A1 (en) * 2022-03-31 2024-10-03 Mayo Foundation For Medical Education And Research Methods and materials for treating pancreatic diseases and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA859575B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IL97148A (en) * 1990-02-26 1996-11-14 Hoffmann La Roche Oxetanones a process for their manufacture and pharmaceutical compositions containing them
FR2754827B1 (fr) 1996-10-17 1998-12-24 Biocem Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations
FR2758143B1 (fr) 1997-01-07 1999-02-19 Laphal Laboratoire De Pharmaco Inhibiteurs specifiques de la lipase pancreatique et leurs applications
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040018197A1 (en) 2002-04-26 2004-01-29 Promega Corporation Treatment for weight loss
DE102004009076A1 (de) 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1803714A1 (en) 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
WO2009059046A1 (en) 2007-10-31 2009-05-07 Burnham Institute For Medical Research Beta-lactone compounds
US9023887B2 (en) 2011-04-15 2015-05-05 University of Pittsburgh—of the Commonwealth System of Higher Education Lipase inhibitors for the treatment of pancreatitis and organ failure
US20150099800A1 (en) 2012-05-24 2015-04-09 Northeastern University Novel lipase inhibitors, reporter substrates and uses thereof
CN106470804B (zh) 2014-06-30 2019-09-10 工机控股株式会社 电动工具
WO2016102541A1 (en) 2014-12-22 2016-06-30 Université Libre de Bruxelles Composition comprising vancomycin and orlistat
US20180319894A1 (en) 2015-11-03 2018-11-08 Mayo Foundation For Medical Education And Research Using colipase inhibitors to treat pancreatitis
SG11202000239XA (en) 2017-07-12 2020-02-27 Mayo Found Medical Education & Res Compounds for the reducing lipotoxic damage

Also Published As

Publication number Publication date
US11976040B2 (en) 2024-05-07
EP4218753A3 (en) 2023-10-11
US11339126B2 (en) 2022-05-24
PL3651784T3 (pl) 2023-06-19
US20250340512A1 (en) 2025-11-06
US20230250057A1 (en) 2023-08-10
RU2020105488A3 (https=) 2021-08-27
EP4218753B1 (en) 2025-12-03
AU2018300985A1 (en) 2020-01-30
AU2018300985B2 (en) 2024-09-12
JP2020527138A (ja) 2020-09-03
EP4218753A2 (en) 2023-08-02
WO2019014434A1 (en) 2019-01-17
CN111343999B (zh) 2022-03-01
ES2934883T3 (es) 2023-02-27
SG11202000239XA (en) 2020-02-27
CN111343999A (zh) 2020-06-26
IL271884A (en) 2020-02-27
EP3651784A1 (en) 2020-05-20
EP3651784A4 (en) 2021-05-05
IL271884B2 (en) 2023-07-01
RU2020105488A (ru) 2021-08-12
EP3651784B1 (en) 2022-09-28
US20210139421A1 (en) 2021-05-13
CA3069526A1 (en) 2019-01-17
US20240343688A1 (en) 2024-10-17
AU2024278291A1 (en) 2025-01-09
KR102679975B1 (ko) 2024-06-28
DK4218753T3 (da) 2026-03-09
US11623915B2 (en) 2023-04-11
US12325690B2 (en) 2025-06-10
BR112020000635B1 (pt) 2023-04-18
IL271884B1 (en) 2023-03-01
BR112020000635A2 (pt) 2020-07-14
JP7224331B2 (ja) 2023-02-17
US20220324797A1 (en) 2022-10-13
KR20200027975A (ko) 2020-03-13

Similar Documents

Publication Publication Date Title
LT3830254T (lt) Naujosios esterazės ir jų panaudojimas
IL271999A (en) TYK2 inhibitors and uses thereof
IL286785B (en) Enzymes and their applications
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
EP3587419A4 (en) FGFR INHIBITOR AND APPLICATION OF IT
IL267925B (en) hsd17b13 variants and their uses
IL272649A (en) AHR inhibitors and their uses
IL270330B (en) Beta-lactamase inhibitors and their uses
IL281171A (en) Cellulose-synthase-like enzymes and their uses
GB201605126D0 (en) Inhibitors and their uses
IL263949A (en) Complement inhibitors and their uses
LT3621694T (lt) Lrrc33 inhibitoriai ir jų panaudojimas
IL262400A (en) Erbb inhibitors and uses thereof
IL287503A (en) Thio-semicarbazide compounds and their use
ZA201807056B (en) Conjugated c1 esterase inhibitor and uses thereof
EP3731840A4 (en) NADPH OXIDASE INHIBITORS AND THEIR USE
PL4218753T3 (pl) Nowe inhibitory lipazy i ich zastosowania
IL280408A (en) CDK inhibitors and uses thereof
IL280369A (en) Myokines and their uses
ZA202002825B (en) Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof
HK40026667A (en) Ahr inhibitors and uses thereof
GB201719989D0 (en) Enzyme inhibitors
GB201719886D0 (en) Enzyme inhibitors
HK40011212A (en) Hsd17b13 variants and uses thereof
GB201620551D0 (en) Enzymes and uses thereof